Öz
The aim of this study was to evaluate the efficacy of oral terbutaline in the treatment of cases with early and late periods of priapism. Results belonging to 73 patients between the age of 28 and 56 (mean age 38.4), with priapism secondary by intracavernous injection of vasoactive agents, were evaluated retrospectively. Patients were divided into three groups as: applicants in the first 8 h (Group 1, n=25), applicants between 8 and 16 h (Group 2, n=29), and applicants later than 16 h (Group 3, n=19). Ten miligrams of terbutaline was given orally to all patients and the outcomes were evaluated following a 1-h waiting period. After the oral administration of terbutaline, penile detumescence were obtained 14 (56%), 10 (34.4%), and 1 (5.2%) patients in groups 1, 2, and 3, respectively. The differences between the groups were found to be statistically significant (p
Anahtar Kelimeler
Kaynakça
- Wasmer JM, Carrion HM, Mekras G, Politano VA. Evaluation and treatment of priapism. J Urol 1981;125:204-7.
- 2. Van der Horst C, Stuebinger H, Seif C, Melchior D, MartínezPortillo FJ, Juenemann KP. Priapism-etiology, pathophysiology and management. Int Braz J Urol 2003;29(5):391-400.
- 3. Keoghane SR, Sullivan ME, Miller MA. The aetiology, pathogenesis and management of priapism. BJU Int 2002;90(2):149-54.
- 4. Ciampalini S, Savoca G, Buttazzi L, Gattuccio I, Mucelli FP, Bertolotto M, et al. High-flow priapism: Treatment and longterm follow-up. Urology 2002;59(1):110-3.
Öz
Priapizm olgularında erken ve geç dönemde oral terbutalin kullanımının etkinliğinin ortaya konması amaçlandı. İntrakavernozal vazoaktif ilaç injeksiyonu sonrası priapism gelişen, yaş aralığı 28-56 (ortalama 38,4) yıl olan 73 hastaya ait sonuçlar retrospektif olarak incelendi. Hastalar intrakavernozal enjeksiyondan sonra ilk 8 saatte başvuranlar (Grup 1, n=25), 8-16. saatler arasında başvuranlar (Grup 2, n=29) ve daha sonra başvuranlar (Grup 3, n=19) olarak üç gruba ayrıldı. Tüm hastalara terbutaline 5 mg oral olarak verildi ve 1 saatlik bekleme süresini takiben sonuçlar değerlendirildi. Grup 1, 2 ve 3'deki hastalarda sırasıyla 14 (%56), 10 (%34.4) ve 1 (%5.2) hastada oral terbutalin kullanımı sonrasında detümesans oluştu. Gruplar arasındaki farklar istatistiksel olarak anlamlı bulundu (p
Anahtar Kelimeler
Kaynakça
- Wasmer JM, Carrion HM, Mekras G, Politano VA. Evaluation and treatment of priapism. J Urol 1981;125:204-7.
- 2. Van der Horst C, Stuebinger H, Seif C, Melchior D, MartínezPortillo FJ, Juenemann KP. Priapism-etiology, pathophysiology and management. Int Braz J Urol 2003;29(5):391-400.
- 3. Keoghane SR, Sullivan ME, Miller MA. The aetiology, pathogenesis and management of priapism. BJU Int 2002;90(2):149-54.
- 4. Ciampalini S, Savoca G, Buttazzi L, Gattuccio I, Mucelli FP, Bertolotto M, et al. High-flow priapism: Treatment and longterm follow-up. Urology 2002;59(1):110-3.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Bölüm | Makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 1 Şubat 2011 |
| Yayımlandığı Sayı | Yıl 2011 Cilt: 17 Sayı: 1 |